Clinical Trial Update: Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013) [EARLY_Phase 1]

View source ↗

Summary

Phase 0/1 biomarker and pharmacodynamic study of roflumilast in patients with advanced B-cell lymphoid malignancies has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoid Malignancies

Drugs mentioned

• Roflumilast (roflumilast)

Snippet

Sponsor: Anand B. Karnad | Conditions: Advanced B-cell Lymphoid Malignancies | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2017-02-27